drugset / Trial / NCT00923611
Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients
Phase 2
Completed
182 enrolled
Boryung Pharmaceutical Co., Ltd
Asan Medical Center · collabCheil General Hospital and Women's Healthcare Center · collabSamsung Medical Center · collabSeoul National University Bundang Hospital · collabSeoul National University Hospital · collabSeverance Hospital · collabThe Catholic University of Korea · collabYonsei University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the antihypertensive efficacy and tolerability of 8 week treatment with Fimasartan (BR-A-657-K) 20, 60, 120, 240 mg and placebo in patients with mild to moderate essential hypertension and to determine the adequate antihypertensive dosage for later clinical study.
Timeline
- Start
- 2007-09
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fimasartan | Small molecule | 20 mg | Oral |
| Comparator | Fimasartan | Small molecule | 60 mg | Oral |
| Comparator | Fimasartan | Small molecule | 120 mg | Oral |
| Comparator | Fimasartan | Small molecule | 240 mg | Oral |